Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.31 · Revenue $2.75M · 3 analysts
Est. EPS $-0.30 · Revenue $2.95M · 2 analysts
Est. EPS $-1.23 · Revenue $7.17M · 1 analysts
Est. EPS $-0.20 · Revenue $2.60M · 1 analysts
EPS $-0.89 · Revenue $618000.00
EPS $-0.93 · Revenue $556000.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.9M | -29.2% | +104.3% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-94.1M | -23.4% | -26.4% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | -16.6% | -135.4% | +875.4% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -4908.2% | -69.3% | +36.8% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -4921.3% | -74.4% | +38.1% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-79.8M | -25.6% | +25.6% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -4169.2% | -77.5% | +63.6% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -2453.8% | -110494.7% | -1.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.73x | -83.7% | -32.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $23.0M | -71.5% | -7.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.55 vs -2.26 | -12.7% | -0.30 vs -0.31 | +4.3% |
| Revenue Surprise | $1.9M vs $1.8M | +6.3% | $1.0M vs $2.8M | -63.3% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | L1 Capital Pty Ltd | 10 percent owner | Common Stock | D | 7,800 | $8.83 |
| Aug 19, 2026 | St Denis David | director, officer: Chief Operating Officer | Common Stock | A | 60,000 | $5.65 |
| Aug 19, 2026 | St Denis David | director, officer: Chief Operating Officer | Common Stock | D | 45,072 | $9.58 |
| Aug 19, 2026 | St Denis David | director, officer: Chief Operating Officer | Stock Options | D | 60,000 | $5.65 |
| Aug 11, 2026 | L1 Capital Pty Ltd | 10 percent owner | Common Stock | D | 375,815 | $9.30 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Wayne Geoffrey Paterson | Vice Chairman & Chief Executive Officer | USD 1,671,101 | Male | 1967 | Active |
David Denis | President & Director | USD 981,905 | Male | 1969 | Active |
Matthew McDonnell | Chief Financial Officer | USD 457,352 | Male | 1974 | Active |
Chris Meduri | Chief Medical Officer & Member of Medical Advisory Board | — | — | — | Active |
BlackRock Inc. bought a new position in shares of Anteris Technologies Global Corp. (NASDAQ: AVR) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,771,213 shares of the company's stock, valued at approximately $56,846,000. BlackRock Inc. owned approximately 5.93%
MINNEAPOLIS and BRISBANE, Australia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson, will be presenting at the Cantor Global Healthcare Conference, the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. The details of each conference are as follows: Cantor Global Healthcare Conference Date: Wednesday, September 9, 2026 (US time) Format: Fireside chat with analyst, Gabie Ingoglia, and 1x1 meetings Time: 11:30AM (US EST) Room: Track 1 – Metropolitan Room Location: Waldorf Astoria Hotel, New York Wells Fargo Healthcare Conference Date: Thursday, September 10, 2026 (US time) Format: Fireside chat with analyst, Larry Biegelsen, and 1x1 meetings Time: 9:30AM (US EST) Room: Track 1 – Picasso 6 Location: Encore Boston Harbor Hotel, Boston Morgan Stanley Healthcare Conference Date: Monday, September 14, 2026 (US time) Format: Fireside chat with Morgan Stanley Healthcare Team Time: 9:15AM (US EST) Room: Soho Complex 7th Floor Location: Sheraton Times Square Hotel, New York About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function.
ADAR1 Capital Management LLC bought a new position in shares of Anteris Technologies Global Corp. (NASDAQ: AVR) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,145,096 shares of the company's stock, valued at approximately $30,979,000. Anteris Technologies
Assenagon Asset Management S.A. bought a new stake in Anteris Technologies Global Corp. (NASDAQ: AVR) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 644,668 shares of the company's stock, valued at approximately $6,350,000. Assenagon Asset Management S.A.
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. Q2 2026 Highlights Secured U.S. Medicare reimbursement eligibility for the global pivotal PARADIGM Trial under a Centers for Medicare & Medicaid Services (CMS) national coverage policy, enabling reimbursement for eligible procedures at U.S. sites.
